A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 153 participants.

Also called NCT02608697

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 153 participants (enrolled count) (from the registry)
Sponsor
Catabasis Pharmaceuticals (from the registry)
Registry
  • NCT NCT02608697
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02608697. Randomized; quadruple masking; primary purpose treatment. Start 2015-10 (registry gives no type); primary completion 2016-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Condition
Hypercholesterolemia
Intervention (Drug)
CAT-2054
Intervention (Drug)
Placebo
Intervention (Drug)
Atorvastatin
Lead sponsor
Catabasis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct02608697
Content hash
132e7668326f9449e9b712942e44a63eafc70035c7b126aea64a67250e378a88